Study: The Cost-effectiveness of Polivy Depends on Outcomes
June 20, 2022
A study in the journal Blood has found that the cost-effectiveness of the Polivy treatment regimen used to treat patients with diffuse large B-cell lymphoma would decrease if the five-year progression-free survival decreased.